TherapeuticsMD Inc（TXMD）資訊與事件TXMDTherapeuticsMD Inc

Company Reports Q1 Revenue of $724K, Up 84% YoY

Reports Q1 revenue $724K vs. $393K y/y. The Company continues to evaluate a variety of strategic alternatives that may include, but are not limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not established a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary. Balance Sheet

TherapeuticsMD Announces Q3 Earnings Per Share of 0c Compared to (5c) Last Year

As of September 30, 2025, the Company's cash and cash equivalents totaled $7.1 million. The Company "continues to evaluate a variety of strategic alternatives that may include, but not be limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not set a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary."

TherapeuticsMD reports Q2 EPS 5c vs. (9c) last year

License revenue, primarily from the Mayne License Agreement, totaled $1.0 million for the second quarter of 2025, an increase of $0.7 million, compared to $234 thousand in license revenue for the second quarter of 2024. The increase is primarily attributable to changes in sales of licensed products.